Clinical Trials on Waldenstrom's Macroglobulinemia Refractory in China

Total 465 results

BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, United Kingdom, Australia, France, China, Spain, Greece
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (BDH-WM01)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (BDH-WM02)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
The First Affiliated Hospital of Soochow University

Unknown

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Treatment

China
Janssen Research & Development, LLC

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

China
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
Sunshine Lake Pharma Co., Ltd.

Completed

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

China
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

Refractory Neoplasms

China
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms

Refractory Neoplasms

China
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms

Refractory Neoplasms

China
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
Ruijin Hospital

Recruiting

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Refractory Solid Tumors

China
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

Refractory Solid Tumor

China
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

Refractory Solid Tumor

China
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Xinxiang medical university

Recruiting

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Relapsed/Refractory Solid Tumors

China
Tianjin Medical University Second Hospital

Recruiting

MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors

Refractory Solid Tumors | Next Generation Sequencing

China
Minghui Pharmaceutical (Shanghai) LTD

Recruiting

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

China
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Mesothelin-positive Advanced Refractory Solid Tumors

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors (CART-HER-2)

Advanced HER-2 Positive Solid Tumors | Chemotherapy Refactory | HER-2 Antibody Inhibitor Therapy Refactory

China
Shanghai Changzheng Hospital

Unknown

Arsenic Trioxide for Structural p53 Mutations

Refractory Cancer | Arsenic Trioxide | p53 Mutations | Intractable Cancer

China
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Relapsed/Refractory AML

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Relapsed/Refractory AML

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
EdiGene (GuangZhou) Inc.
The First Affiliated Hospital of Henan University of Science and Technology

Active, not recruiting

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

China
The Affiliated Hospital of the Chinese Academy...
Chinese PLA General Hospital

Unknown

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

Relapsed and/or Refractory CD33+ AML

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Refractory Leukemia

China
Peking University

Unknown

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Refractory Malignant Ascites

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Glucocorticoid-Refractory aGVHD

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Fudan University

Recruiting

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
The First Affiliated Hospital of Xiamen University

Recruiting

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Refractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML

China
Allergan

Completed

Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma

Refractory Glaucoma

China
TCRx Therapeutics Co.Ltd

Recruiting

KSX01-TCRT Injection Project in Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors | TCR-T Cells

China
Second Affiliated Hospital of Soochow University

Recruiting

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Advanced Refractory Solid Tumors

China

Clinical Trials on Waldenstrom's Macroglobulinemia Refractory in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations